Gastroesophageal Reflux Disease — Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn
Citation(s)
A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (60 mg Once-Daily (QD) and 90 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD)